Who is sponsoring NCT03404622?

NCT03404622 is sponsored by ALshaimaa Aboalhassan Ali.

What drugs are being tested in NCT03404622?

Interventions in NCT03404622: IUCD.

What condition does NCT03404622 study?

NCT03404622 studies Mechanical Complication of Intrauterine Device.

Is NCT03404622 still recruiting?

NCT03404622 is currently completed. Last updated 29 January 2018.

Last reviewed 2018-01-29 · How we verify

NCT03404622

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immediate Post-placental Insertion of IUCD During Cesarean Delivery Versus 6 Week Post-Cesarean Insertion

Completed Phase 1 Last updated 29 January 2018

What this trial tests

Phase 1 trial testing IUCD in Mechanical Complication of Intrauterine Device in 200 participants. Completed in 20 December 2017.

Timeline

20 September 2016

Primary endpoint
20 December 2016

20 December 2017

Quick facts

Lead sponsor	ALshaimaa Aboalhassan Ali
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	health services research
Enrollment	200
Start date	20 September 2016
Primary completion	20 December 2016
Estimated completion	20 December 2017
Sites	1 location across Egypt

Drugs / interventions tested

IUCD — full drug profile →

Conditions studied

Mechanical Complication of Intrauterine Device — all drugs for Mechanical Complication of Intrauterine Device →

Sponsor

ALshaimaa Aboalhassan Ali — full company profile →

Who can join

Adults 18 to 45, female only, with Mechanical Complication of Intrauterine Device. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of current study is to compare the rates of IUCD expulsion and complications in immediate post-placental insertion versus delayed IUCD insertion (6-weeks after cesarean delivery)

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Immediate versus delayed postpartum insertion of contraceptive implant and IUD for contraception.
Sothornwit J, Kaewrudee S, Lumbiganon P, Pattanittum P, et al · · 2022 · cited 12× · PMID 36302159 · DOI 10.1002/14651858.cd011913.pub3

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03404622 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ALshaimaa Aboalhassan Ali
Last refreshed: 29 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03404622.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing